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Abstract Environmental influences affecting genet-
ically susceptible individuals seem to contribute
significantly to the development of Parkinson’s dis-
ease (PD). Xenobiotic exposure including transitional
metal deposition into vulnerable CNS regions appears
to interact with PD genes. Such exposure together with
mitochondrial dysfunction evokes a destructive cas-
cade of biochemical events, including oxidative stress
and degeneration of the sensitive dopamine (DA)
production system in the basal ganglia. Recent
research indicates that the substantia nigra degenera-
tion can be decelerated by treatment with iron binding
compounds such as deferiprone. Interestingly
compounds known to decrease PD risk including
caffeine, niacin, nicotine and salbutamol also possess
iron binding properties. Adequate function of antiox-
idative mechanisms in the vulnerable brain cells can
be restored by acetylcysteine supplementation to
normalize intracellular glutathione activity. Other
preventive measures to reduce deterioration of
dopaminergic neurons may involve life-style changes
such as intake of natural antioxidants and physical
exercise. Further research is recommended to identify
therapeutic targets of the proposed interventions, in
particular protection of the DA biosynthesis by oxygen
radical scavengers and iron binding agents.
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Introduction
Parkinson’s disease (PD) affects at least 6 million
people worldwide (Kalia and Lang 2016) and typically
occurs in people over the age of 60, of whom about one
percent are affected (Global Burden of Disease Cancer
et al. 2017). Life expectancy is moderately reduced yet
PD mortality doubles some 15 years after the diagno-
sis. PD is a progressive disorder of the brain where
dopamine-producing cells located in the substantia
nigra (SN) degenerate. Dopamine (DA) synthesized in
SN is an important neurotransmitter depleted both in
PD and other movement disorders (Bernheimer et al.
1973). The precursor of DA known as L-dopa origi-
nates from the amino acid L-tyrosine through the
action of the enzyme tyrosine hydroxylase that uses
oxygen and iron (Fe) as cofactors (Fig. 1). Dopamine
is transported extracellularly by the DA active trans-
porter to synaptic receptors on neurons located in the
striatum, nucleus accumbens, hippocampus, neocor-
tex, and to the spinal cord. Dopamine deficiency in the
nigrostriatal pathway is the ultimate cause of the
parkinsonian syndrome, i.e. presence of bradykinesia
and at least one of rigidity or resting tremor (Postuma
et al. 2015).
Neurodegenerative changes in PD are associated
with progressive alpha-synuclein aggregation and
clinical symptoms developing slowly over time. It
has been shown that alpha-synuclein pathology with
Lewy bodies is present in gut myenteric plexus and
olfactory nerve decades before motor symptoms
develop. According to prevailing theory, the progres-
sive alpha-synuclein pathology occurs in a prion-like
manner and ultimately affects the entire nervous
system. Some neuronal populations appear to be more
vulnerable to the alpha-synuclein pathology than
other. This is the case of SN dopaminergic neurons,
which are prominently affected by neurodegeneration
in PD (Poewe et al. 2017). Neither the etiology of the
alpha-synuclein related neurodegeneration nor the
cause of the vulnerability of dopaminergic cells is
currently known. It is however clear that ageing, as
well as genetic and environmental factors are involved
(Kalia and Lang 2016). Specific mutations (Kalinderi
et al. 2016) in genes causing familial PD as well as
polymorphisms increasing the risk of PD have been
identified. Interestingly, mechanisms of these muta-
tions appear to converge on disrupted synaptic,
endosomal, and lysosomal trafficking ultimately lead-
ing to overwhelming of cellular disposal mechanisms
(Abeliovich and Gitler 2016).
Apparently the development of PD is characterized
by three different biochemical dysfunctions, viz.
abnormal protein aggregation, inhibition of mitochon-
drial complex 1, and oxidative stress (Dauer and
Przedborski 2003; Tanner et al. 1989). In normal
healthy states, aggregates of alpha-synuclein are
cleared by autophagy provided adequate activity of
leucine-rich repeat kinase 2 (LRRK2) is present
(Volpicelli-Daley et al. 2016). Mutations in the
LRRK2 gene have been noted in sporadic and in
familial PD (Berg et al. 2005). Mutations in other
genes, i.e. the SNCA gene (the alpha-synuclein gene),
also represent risk factors for PD (Kalinderi et al.
2016).
However, genetic background is considered to
account for only about 10% of PD cases, suggesting
that other factors play a crucial role in the pathogen-
esis. History of recent cranial trauma (Fang et al.
2012a) and CNS infections (Fang et al. 2012b) as well
as environmental factors such as exposure to fungi-
cides and pesticides, e.g., maneb, rotenone and
paraquat (Costello et al. 2009; Tanner et al. 2011)
seem to be involved in the pathogenic process. There
is ongoing discussion whether chronic low-level
exposure to various metals such as manganese may
Fig. 1 The enzyme tyrosine hydroxylase uses three cofactors,
viz. Fe(II), molecular oxygen and tetrahydrobiopterin (BH4) in
the biosynthesis of L-dopa. One of the oxygen atoms in O2 is
used to hydroxylate the tyrosine molecule in meta-position to L-
dopa, and the other is used to hydroxylate the cofactor BH4. The
oxidation state of the iron atom is crucial. If the Fe(II) is
oxidized to Fe(III), or replaced by another metal, the enzyme is
inactivated. Inappropriate interactions between Fe, or other
transition metals, with the enzyme or its reactants generate toxic
amounts of reactive oxygen species
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also be a risk factor for PD (Lucchini et al. 2009).
Furthermore, extensive epidemiological research has
identified several factors, such as tobacco smoking,
drinking tea or coffee, use of NSAID, statins, salbu-
tamol, and physical activity (Yang et al. 2015) to pose
a reduced risk to develop PD (Ascherio and Sch-
warzschild 2016; Barranco Quintana et al. 2009;
Noyce et al. 2012). It is an interesting question
whether these factors may prevent aggregation of
alpha-synuclein itself or protect vulnerable cellular
populations from its toxic effects. Indeed, recent
research indicates that there is no correlation between
Lewy body load and dopaminergic neuronal loss in
incidental Lewy body disease and PD cases (Iacono
et al. 2015) suggesting that alpha-synuclein pathology
does not irrevocably lead to neuronal death.
At present there is no effective cure for PD, and the
current treatment is merely symptomatic based on
substitution of dopaminergic deficit. Disease-modify-
ing approaches are urgently needed and understanding
the effects of protective factors identified by epidemi-
ological studies may bring us closer to this goal.
The present review identifies common mechanism
of some preventive measures in PD and highlights
their potential role in ameliorating metal-related
pathology. We also discuss links between metal
exposure, Fe metabolism and DA metabolism.
Dysregulated iron and copper metabolism
and oxidative stress in Parkinson’s disease
The accumulation of Fe observed in SN in association
with the occurrence of aggregated misfolded protein
seems to contribute to the progression of PD (Ward
et al. 2014). One theory claims that pathological
distributions of Fe and copper (Cu) (Dusek et al. 2015;
Genoud et al. 2017; Ward et al. 2014) aggravate
oxidative damage and contribute to PD progression.
Elevated cytosolic Fe in SN of PD patients has long
been associated with neurotoxicity via various mech-
anisms including deleterious interactions between DA
and Fe (Hare and Double 2016). Furthermore, dys-
metabolism of Cu with reduced cytosolic fraction of
the metal, reflecting reduced activity of the cuproen-
zyme superoxide dismutase-1 (SOD1) (Genoud et al.
2017) will also increase the oxidative stress in PD
(Trist et al. 2018). The pathogenic role of the
aggregation of alpha-synuclein, effective as a Cu
chaperone, for the SOD1 insufficiency is unclear
(Barnham and Bush 2008). The alterations in Fe and
Cu distribution appear to occur early in the PD disease
process and are therefore not considered to represent
merely a reactive redistribution of metals secondary to
neuroinflammation (Genoud et al. 2017).
The neurotransmitter precursor L-dopa is synthe-
sized from the amino acid tyrosine by the enzyme
complex tyrosine hydroxylase that uses molecular
oxygen and Fe(II) as cofactors (Fig. 1). This enzyme
complex represents a sensitive biochemical site in the
SN. Transition metal ions, including free ions of Fe,
manganese, and Cu, can catalyze the generation of
ROS around this site, and thereby affect the enzymatic
function of tyrosine hydroxylase negatively. Malfunc-
tion of tyrosine hydroxylase may further speed up
ROS generation, forming a vicious circle of enzymatic
dysfunction and ROS generation accelerating nigros-
triatal cell death. However, the exact mechanisms of
cellular death in PD, starting in the SN pars compacta
and subsequently spreading to other CNS regions, are
yet not fully known (Kalia and Lang 2016). Environ-
mental pollutants contributing in the PD pathogenesis
include 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) (Langston and Ballard 1984), paraquat,
rotenone, and maneb (Liou et al. 1997; Pezzoli and
Cereda 2013; Qi et al. 2014). The toxic effects of
rotenone and MPTP are ascribed to their impact on the
mitochondrial electron transport chain, as they cause a
transport block of electrons in complex 1, leading to
generation of ROS (Gao et al. 2003; Smeyne and
Jackson-Lewis 2005). Paraquat is another catalyst for
the formation of ROS (Bus and Gibson 1984). In rats
paraquat toxicity has been associated with Parkinson-
like neurodegenerations (Ossowska et al. 2006). One
study reported a link between combined exposure to
paraquat and Fe in infancy and mid-life Parkinson’s in
laboratory mice (Peng et al. 2007). Exposure to
maneb, a manganese dithiocarbamate derivative, is
associated with increased deposition of transition
elements in cerebral regions (Aaseth et al. 1981),
thereby apparently causing dopaminergic neurode-
generation (Zhang et al. 2003).
Reduced PD progression by deferiprone and other
iron chelators
A characteristic feature of the PD neuropathology is
the accumulation of Fe in the degenerating SN (Ward
et al. 2014). Although neurodegenerative changes are
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widespread in the PD nervous system, increased Fe
concentrations is apparently limited to SN (Acosta-
Cabronero et al. 2017; Double et al. 2010) where the
most pronounced neuronal loss is reported (Barbosa
et al. 2015). Interactions between electrophilic Fe(III)
ions and an extra-vesicular fraction of DA are assumed
to play a critical role in the progressive cellular
degeneration, initially creating an unstable Fe(III)–
DA-complex, that gives rise to neurotoxic products
especially in SN and related sensitive regions of the
brain (Hare and Double 2016). The unstable Fe(III)–
DA complex appears to bring about the production of
o-quinones (Zhang et al. 2012) and DA-quinones (DA-
quinones), as well as 6-hydroxydopamine (6-OHDA).
The former compounds are basis of the pigment
neuromelanin while the latter agent is a well-known
neurotoxin frequently used in animal PD models.
Inside the cell, unbound DA-quinones react with the
sulfhydryl groups of glutathione (GSH) and protein
thiols to form altered protein structures (Stokes et al.
1999) that cause cellular toxicity and microglial
activation (Asanuma et al. 2003). It has been sug-
gested that formation of 6-OHDA initiates a cascade
of reactions that increases the intracellular labile Fe
pool, thus overwhelming protective antioxidant mech-
anisms (Hare and Double 2016). Other catecholami-
nes also form unstable complexes and toxic products
with Cu(II) or Fe(III) (Aaseth et al. 1998). Interest-
ingly, a more stable chelate is formed between Fe(III)
and the ephedrine derivative, salbutamol (Fatima
2012), a commonly used anti-asthmatic drug.
Intriguingly, use of the latter drug was associated
with significantly decreased risk of developing PD in a
large epidemiological trial. Additional analyses have
shown that the protective effect is likely based on its
documented role as a regulator of the alpha-synuclein
gene decreasing its expression (Mittal et al. 2017). A
large-scale study is about to be launched studying
salbutamol as a disease-modifying agent for PD
(Robinson 2017). It would be interesting to see to
what extent the chelating properties of salbutamol
contribute to its putative neuroprotective effect.
Another metal-binding drug, deferiprone, is a
hydroxy ketone pyridine derivative (Fig. 2) effective
as an Fe chelating agent in clinical settings and known
to cross the blood–brain barrier (Roy et al. 2010).
Devos et al. (2014) studied the effect of conservative
Fe chelation with 30 mg/kg/day of deferiprone in PD
patients. This double-blind placebo-controlled pilot
trial showed that 12 months of deferiprone therapy
decreased disease progression by three points on the
Unified Parkinson’s Disease Rating Scale part III
(UPDRS-III) compared to the placebo group. Addi-
tionally, quantitative R2* transverse relaxometry MRI
technique, a surrogate marker of tissue Fe concentra-
tions, confirmed that deferiprone led to a drop in SN Fe
content (Devos et al. 2014). Another placebo-con-
trolled deferiprone trial in PD patients showed only a
trend for UPDRS-III improvement in the group using
the dose 30 mg/kg/day, but the R2* MRI indicated a
decrease of Fe in the dentate and caudate nuclei in the
active group compared to placebo (Martin-Bastida
et al. 2017). Statistical significance was not reached,
maybe related to the short duration (6 months) of this
trial.
These results support the hypothesis that conserva-
tive Fe chelation may modify natural progression of
Fig. 2 Chemical structures of proposed protective agents
deferiprone, caffeine, niacin and nicotine, showing their
nitrogen and oxygen electron donor groups, responsible for
the affinity to electrophilic ions of transition metals, e.g. Fe(III)
and Cu(II)
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PD. It is possible that Fe chelation may be even more
effective when initiated in prodromal stages of PD.
Caffeine: maybe another iron chelator
Postuma et al. (2012) found that patients with PD
improved by taking caffeine pills for 2 months. For the
study, 61 PD patients with a mean age of 60 years
were selected. In six weeks, 30 of the participants
received caffeine pills in an amount equivalent to two
cups of coffee a day and the remaining 31 subjects got
placebo capsules. At the end of the study, the patients
who had ingested caffeine reported, in addition to less
drowsiness, a general improvement in motor symp-
toms such as muscle stiffness and movement difficul-
ties (Postuma et al. 2012). A larger multicenter follow
up study was however unable to reproduce these
findings (Postuma et al. 2017).
Ross et al. (2000) upon analyzing data collected
during 30 years of follow-up of 8004 Japanese-
American men aged 45–68 enrolled in the study
during the period 1965–1968, identified 102 men with
PD, and noted that high coffee or caffeine intake was
linked to a significantly lower frequency of PD. This
effect appeared to be independent of smoking. Their
data indicated that the mechanism was related to the
caffeine dose and not to other nutrients (Ross et al.
2000). Animal studies (Xu et al. 2016) and meta-
analysis (Costa et al. 2010) have confirmed these
observations. Another meta-analysis has shown an
inverse linear dose–response relationship between PD
risk and amount of coffee, tea or caffeine consumed. It
was found that maximum protection was reached at
about three cups of coffee per day (Qi and Li 2014). In
this context the structural similarities between defer-
iprone and caffeine should be noted (Fig. 2). Protec-
tive effects of caffeine may be related to its ability to
bind Fe via its nitrogen and oxygen groups, albeit with
a lower binding constant than the EDTA-Fe com-
plexes (Andjelkovic´ et al. 2006).
Niacin is a protector with metal binding properties
Vitamin B3, or niacin, also known as nicotinic acid,
may alleviate certain types of early-onset PD symp-
toms (Anderson et al. 2008). Niacin has been shown to
attenuate neuroinflammation through an action on
niacin receptor 1 (NIACR1), also known as GPR109A
and may have a therapeutic potential toward PD
(Wakade and Chong 2014). Although moderate
amounts of niacin are found in a number of foods,
including chicken, turkey, beef, peanut and mush-
rooms, the vitamin can be supplemented in therapeutic
doses as tablets. In MPTP exposed rodents, the
administration of nicotinamide gave a dose-dependent
saving of striatal DA levels and SN neurons (Anderson
et al. 2008). Niacin, which is a precursor for nicoti-
namide adenine dinucleotide (NAD–NADH) needed
for DA production, may serve several purposes, i.e.,
reduce inflammation through NIARC1-related mech-
anisms, increase DA synthesis in the striatum through
NADPH supply and increase NAD/NADH ratio to
restore complex 1 functions in mitochondria. Niacin
can also bind transition metal ions including Fe into
stable complexes (Al-Saif and Refat 2012).
Nicotine and its neuroprotective mechanisms
Nicotine may have a potential to protect against PD,
and pharmaceuticals that target nicotine receptors
have been searched for. In particular, the nicotinic
alpha-7 receptor, implicated in long-term memory
function, has been in the focus of interest (Rang et al.
2003).
Nicotine acts as an agonist to most nicotinic
acetylcholine receptors (Malenka et al. 2009), and
can be used to improve cognition and alertness
(Jasinska et al. 2014). A meta-analysis of 41
placebo-controlled studies concluded that nicotine
had a positive effect on motor abilities, orienting
attention, and working memory (Heishman et al.
2010).
Using rat embryo tissue, Toulorge et al. (2011)
prepared brain cell cultures demonstrating conditions
that favored progressive loss of dopaminergic neu-
rons, which also showed distinctive features otherwise
characterizing PD, and this group also reported a
protective effect of nicotine. In normal mice, nicotine
has been found potentially able to rescue dopaminer-
gic neurons, but apparently not in mice without the
nicotine receptor (Toulorge et al. 2011).
Although one of the developed nicotine receptor
agonists, varenicline, showed only limited protective
effect (Bohnen et al. 2009), further research on
nicotine receptors and nicotine agonists in PD brings
possibilities for early stage neuroprotective treatment
(Barreto et al. 2014; Kelton et al. 2000; Quik 2004).
Interestingly, nicotine also acts as a metal-chelating
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agent, with high affinity for Fe(III) (Fazary 2017).
Thus, it is tempting here to forward the hypothesis that
the PD protecting potential of nicotine is not merely
related to its effects on the receptors, but also to its
ability to pass the blood–brain barrier better than other
chelators and thus act as an intra-neuronal Fe chelating
agent (Zhang et al. 2006).
Glutathione and glutathione peroxidase protect
against neurodegeneration
Another approach to ameliorate cellular deterioration
caused by ROS in PD is to raise the intracellular levels
of the tripeptide glutathione (GSH). Antioxidant
defenses in SN are relatively low, compared to other
regions of CNS, due to low levels of GSH, particularly
during the early stages of PD when extravesicular DA
and its degradation products may act as a GSH
depleting agents (Pearce et al. 1997; Stokes et al.
1999). N-acetylcysteine (NAC) shows antioxidant
properties by restoring cellular GSH, which partici-
pate in important endogenous antioxidant systems. In
experimental studies NAC has been reported to protect
against PD development (Rahimmi et al. 2015).
Glutathione acts either alone or together with an
appropriate enzyme system, viz. glutathione peroxi-
dases (GPXs), to reduce ROS. Also, GSH detoxifies
xenobiotics and maintains sulfhydryl proteins in a
reduced state (Meister and Anderson 1983). The
antioxidant characteristics of GSH have been demon-
strated in several models of oxidative stress, including
models using buthionine-sulfoximine (BSO) to deplete
GSH (Wullner et al. 1996). In these studies, the GSH
depletion increased oxidative stress in whole cells as
well as in mitochondrial fractions. Depletion of GSH
with BSO potentiated the MPTP-induced tyrosine
hydroxylase-positive neuron death in pars compacta of
SN (Wullner et al. 1996). Furthermore, NAC treatment
after MPTP or rotenone exposure in the GSH-depleted
models, restored mitochondrial complex 1 and pro-
tected against DA loss in SN (Chinta et al. 2006).
It is tempting to suggest that supplementation with
NAC in adequate doses to patients with PD may
inhibit disease progression.
In vivo, GSH exerts most of its anti-oxidative
functions as a cofactor to the GPX family of enzymes.
GPXs are a group of selenium-containing enzymes
capable of reducing toxic peroxides (Rotruck et al.
1973); GPX1 is present in both neurons and glial cells
(Power and Blumbergs 2009). Overexpression of GPX
decreases the amount of neuron loss in neurotoxic
conditions (Wang et al. 2003). An immunocytochem-
ical study of GPX1 expression showed that dopamin-
ergic neurons in the SN expressed low levels of this
protein, while other regions not affected in PD,
expressed higher levels (Trepanier et al. 1996). In an
experimental model of GPX1-deficient PD-mice chal-
lenged with MPTP, DA levels in vulnerable regions
decreased (Klivenyi et al. 2000). However, in cortical
samples taken from PD patients, GPX3 and GPX4
proteins were elevated compared to control subjects
(Blackinton et al. 2009), presumably reflecting a
protective response.
A marginal or deficient selenium status as is
reported from Scandinavian regions (Alehagen et al.
2016; Ellingsen et al. 2009) and other parts of Europe
involve a deficient GPX-dependent protection (Ale-
hagen et al. 2017), also with regard to nigrostriatal
functions. To the knowledge of the authors, clinical
studies with selenium supplementation in early stages
of PD in these regions have yet not been carried out.
Non-steroidal anti-inflammatory drugs
Neuroinflammation contributes to degeneration of the
dopaminergic nigrostriatal pathway in PD
(Vivekanantham et al. 2015) through mechanisms of
microglial activation. Pro-inflammatory phenotype of
microglia is promoted by extracellular alpha-synu-
clein aggregates and neuromelanin complexes
released from dying neurons (McGeer et al. 1988).
Neuromelanin contains high concentration of various
metals, namely Fe, Cu and Mn that may themselves
contribute to inflammation (Tansey and Goldberg
2010). Neuroinflammation in PD is rather widespread
as increased inflammatory markers, such as TNFa,
IFNc, IL-6, IL-1b, and other cytokines are consis-
tently detected in serum and cerebrospinal fluid of PD
patients (Brodacki et al. 2008). Neuroinflammation is
also an early event in neuronal degeneration since
microglial activation has been documented by PET in
patients with isolated REM sleep behavioral disorder,
considered a prodromal synucleinopathy (Stokholm
et al. 2017). Given that several genes causing PD,
namely LRRK2, GBA, and SNCA, are expressed
predominantly in immune cells and/or are involved
in regulating inflammatory response, the emerging
hypothesis is that inflammatory dysregulation is a
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primary trigger of neurodegeneration (Dzamko et al.
2015). However, it is not clear to what extent is the
activation of immune cells is deleterious with respect
to disease progression. On one side, microglial
phagocytosis may clear abnormal protein aggregates,
on the other side, neurotoxic effects of chronic
inflammatory reaction may accelerate neuronal loss
(Deleidi and Gasser 2013).
According to epidemiological data, non-steroidal
anti-inflammatory drugs (NSAIDs) can reduce the risk
of developing PD (Asanuma et al. 2004; Chen et al.
2003; Wahner et al. 2007). These results are appar-
ently in line with immunocytotoxic theories of neu-
rodegeneration, and a neuroprotective effect of
NSAID was initially ascribed to cyclooxygenase
type-2 inhibition (Teismann et al. 2003). However,
other studies did not confirm reduced PD risk in the
NSAID users compared to controls (Becker et al.
2011; Etminan and Suissa 2006). Later studies
detailed the effect of NSAID, and Wahner et al.
(2007) reported that reduced risk of getting PD in
NSAID users was seen only among regular users and
the effect was particularly strong (OR 0.44) in people
who regularly used non-aspirin NSAIDs (Wahner
et al. 2007). A meta-analysis by Gagne and Power
(2010) revealed only a moderately reduced risk of
about 15% in non-aspirin NSAID users while no
protective effect was observed in aspirin users (Gagne
and Power 2010). More specifically, only regular use
of ibuprofen was associated with significant reduction
of PD risk (pooled OR 0.73) in a study and meta-
analysis of several NSAIDs (Gao et al. 2003). Taken
together, the fact that ibuprofen use, but not use of
other NSAIDs, was associated with lower PD risk
suggests mechanisms other than a generic anti-
inflammatory activity. It is possible that only some
few NSAIDs act protective, owing to their ability to
form Cu, manganese or Fe chelates (Duncan and
White 2012). Interestingly, it was suggested that
ibuprofen possesses Fe chelating (Kennedy et al.
1990) or hydroxyl scavenging (Hamburger and
McCay 1990) properties. Of interest is also that some
Cu-chelates of NSAIDs appear to show SOD-mimetic
activity (Roberts and Robinson 1985).
Exercise
Parkinson’s disease can be delayed, or its conse-
quences attenuated through regular safe physical
activity. Recent scientific studies suggest a combina-
tion of aerobic activities, strength training from
moderate to high intensity, as well as balance training,
gait training, functional activities and exercises that
require agility (Fisher et al. 2008; Goodwin et al.
2008). Experimental studies indicate that the inflam-
matory response is reduced, insulin sensitivity
improved and damage to dopaminergic neurons
reduced when exercise is combined with intermittent
fasting (Mattson 2014).
Physiotherapeutic treatment should be started as
soon as the diagnosis is confirmed and is a good way to
help stimulate movement and quality of life as it
improves the strength, coordination, and amplitude of
the movements, i.e., by reducing the otherwise inex-
orable imbalance characterizing the progressive dis-
ease, thereby preventing contractures and falls
(Ahlskog 2011).
Conclusion
Environmental factors including exposure to metals,
pesticides and drugs account for the majority of cases
of Parkinsons disease. Excessive oxidative stress
accentuated by iron accumulation and abnormal
protein aggregation in the nigrostriatal region of the
brain are primary events in the development of the
disease that need to be addressed by preventive
measures. Iron is a necessary cofactor for the enzyme
tyrosine hydroxylase responsible for DA synthesis,
and accumulation of Fe in the SN deteriorates the
function of tyrosine hydroxylase. Metal binding
substances e.g. Deferiprone mobilize Fe from the SN
possibly providing prevention. Caffeine, niacin, nico-
tine and salbutamol also seem to protect against
progression by similar mechanisms. Supplementation
with NAC together with selenium for optimal glu-
tathione synthesis is recommended to reduce oxidative
damage to sensitive SN cells.
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